BioNxt Solutions Nears Key Patent Milestone for MS Therapy
Published on 11/02/2025 at 05:04 | Redaktion boerse-global.de
BioNxt Solutions, a Canadian life sciences company, has reached a significant regulatory milestone that could strengthen its intellectual property portfolio. The company announced Thursday that it received a “Readiness to Grant” notification from the Eurasian Patent Organization for its sublingual Cladribine treatment targeting multiple sclerosis.
This development represents a crucial step forward in protecting BioNxt’s proprietary technology platform. Rather than developing entirely new chemical entities, the company focuses on reformulating existing approved medications into more patient-friendly delivery systems. Their sublingual film technology dissolves rapidly when placed under the tongue, potentially enabling faster absorption and improved bioavailability compared to traditional oral medications.
Despite this positive regulatory development, investor Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
